Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 8Phase 1 7Phase 1/2 5

Status

Active not recruiting 3Recruiting 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Carcinoma, Renal Cell 4Parkinson Disease 4, Autosomal Dominant Lewy Body 2Metastatic Castration-Resistant Prostate Cancer 1Kidney Neoplasms 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × belzutifan × Clear all
NCT07049926 2026-05-26

MK-3475-03C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
140 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT04626479 2026-05-18

MK-3475-03A

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
400 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04626518 2026-05-06

KEYMAKER-U03

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
370 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02861573 2026-02-17

KEYNOTE-365

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
1,200 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT05468697 2026-01-23

MK-6482-024

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
60 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡